|
Market Closed -
Nasdaq
16:00:00 2026-10-30 EDT
|
5-day change | 1st Jan Change | ||
| 96.56 USD | -2.43% |
|
+6.90% | +194.75% |
| 10-20 | Spyre's Ulcerative Colitis Combo Approach Gains Support From AbbVie Data, UBS Says | MT |
| 10-12 | UBS Initiates Spyre Therapeutics at Buy With $120 Price Target | MT |
| Market Cap | 9.02B 8.08B 7.43B 6.74B 12.59B 857B 12.83B 88.65B 35.59B 451B 33.87B 33.15B 1,421B | P/E 2026 * |
-33.5x | P/E 2027 * | -26.7x |
|---|---|---|---|---|---|
| Enterprise Value | 8.46B 7.57B 6.97B 6.31B 11.8B 803B 12.02B 83.06B 33.34B 422B 31.73B 31.06B 1,332B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
93.73% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| SYRE | Delayed | |
CBOE
| SYRE | Real-time | |
|
Tradegate
| 3920 | Real-time | |
|
Deutsche Boerse AG
| 3920 | Delayed | |
|
Börse Stuttgart
| 3920 | Delayed | |
|
Boerse Muenchen
| 3920 | Real-time | |
|
Xetra
| 3920 | Delayed |
Last Transcript: Spyre Therapeutics, Inc.
| 1 day | -2.43% | ||
| 1 week | +6.90% | ||
| Current month | +8.46% | ||
| 1 month | +8.46% | ||
| 3 months | -4.87% | ||
| 6 months | +29.70% | ||
| Current year | +194.75% |
| 1 week | 90.35 |  | 100.42 |
| 1 month | 76.87 | | 100.42 |
| Current year | 28 | | 110.18 |
| 1 year | 21.14 | | 110.18 |
| 3 years | 8.43 | | 110.18 |
| 5 years | 2.66 | | 198.5 |
| 10 years | 2.66 | | 300 |
| Manager | Title | Age | Since |
|---|---|---|---|
Cameron Turtle
CEO | Chief Executive Officer | 36 | 2023-11-26 |
Scott Burrows
DFI | Director of Finance/CFO | 49 | 2023-08-31 |
Joshua Friedman
CTO | Chief Tech/Sci/R&D Officer | - | 2023-11-26 |
| Director | Title | Age | Since |
|---|---|---|---|
Cameron Turtle
BRD | Director/Board Member | 36 | 2023-11-26 |
Tomas Kiselak
BRD | Director/Board Member | 40 | 2023-06-21 |
| Director/Board Member | 36 | 2023-06-21 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 10/1/26 | Exercice | General Counsel | 86,799 | 0.0984% | ||
| 10/1/26 | Exercice | Chief Financial Officer | 22,500 | 0.0255% | ||
| 10/1/26 | Sell | Chief Executive Officer | -15,000 | 0.0170% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.43% | +6.90% | +298.02% | +726.71% | 9.02B | |
| -0.62% | -1.87% | +46.31% | +56.99% | 63.77B | |
| +0.35% | +3.20% | +14.92% | +84.55% | 56.37B | |
| +0.53% | +1.96% | +15.37% | +106.81% | 54.62B | |
| -2.81% | -4.31% | +23.50% | +50.90% | 44.06B | |
| -0.33% | -1.93% | +20.15% | +98.45% | 42.11B | |
| +0.55% | +2.31% | +224.97% | +942.56% | 41B | |
| +3.27% | +47.96% | +112.67% | +96.48% | 34.92B | |
| +1.22% | -1.44% | +14.89% | +47.15% | 32.82B | |
| +0.89% | +20.55% | -42.03% | +373.03% | 24.7B | |
| Average | +0.06% | +7.48% | +72.88% | +258.36% | 40.34B | |
| Weighted average by Cap. | +0.12% | +5.48% | +54.08% | +198.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -258M -231M -212M -192M -360M -24.47B -366M -2.53B -1.02B -12.87B -967M -947M -40.6B | -340M -304M -280M -254M -474M -32.28B -483M -3.34B -1.34B -16.98B -1.28B -1.25B -53.55B |
| Net Debt | -569M -509M -468M -424M -793M -53.99B -808M -5.59B -2.24B -28.4B -2.13B -2.09B -89.56B | -610M -546M -503M -455M -851M -57.92B -867M -5.99B -2.41B -30.47B -2.29B -2.24B -96.09B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-30 | US$96.56 | -2.43% | 661,126 |
| 26-10-29 | US$98.96 | -0.79% | 567,636 |
| 26-10-28 | US$99.75 | +0.71% | 724,549 |
| 26-10-27 | US$99.05 | +6.60% | 944,931 |
| 26-10-26 | US$92.91 | +2.86% | 637,181 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SYRE Stock
Select your edition
All financial news and data tailored to specific country editions
